Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GE226
- Development stage
- Unknown
- Lead developer
- Affibody
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
GE226 (also known as [18F]GE-226 or GE121224) is an 18F-labeled diagnostic radiopharmaceutical developed for positron emission tomography (PET) imaging of human epidermal growth factor receptor 2 (HER2) expression. It consists of the HER2-targeting affibody molecule ZHER2:2891 site-selectively conjugated with [18F]4-fluorobenzaldehyde ([18F]FBA). GE226 binds to a different epitope on the HER2 receptor than trastuzumab, allowing non-invasive assessment of HER2 status in patients with locally advanced or metastatic breast cancer to guide therapy selection and monitor treatment response. The agent was originally developed by GE Healthcare in partnership with Affibody, and has been evaluated in Phase 1 clinical trials sponsored by Imperial College London.
- Other names
- [18F]FBA-ZHER2:2891[18F]GE-226[18F]GE22618F-GE-22618F-GE226fluorine-18 GE-226fluorine18 GE-226fluorine 18 GE-226fluorine-18 GE226fluorine18 GE226fluorine 18 GE226
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on GE226.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GE226.